摘要
目的:研究南京地区2016~2018年白蛋白及免疫球蛋白类生物制品的临床利用趋势。方法:对南京地区37家医院2016~2018年白蛋白及免疫球蛋白类生物制品的品种、销售金额、构成比、用药频度(DDDs)、限定日费用(DDC)等进行统计分析。结果:白蛋白及免疫球蛋白类生物制品的使用总金额逐年增长,平均年增长率19.54%,其中人血白蛋白、静注人免疫球蛋白和狂犬病人免疫球蛋白3种药物3年销售金额均排在前3位,且所占比例均超过90%。而人血白蛋白、静注人免疫球蛋白和乙型肝炎人免疫球蛋白3种药物3年DDDs均排在前3位。结论:南京地区白蛋白及免疫球蛋白类生物制品临床应用广泛,使用量和销售金额整体均呈快速增长趋势。
Objective:To reserach the utilization trends of albumin and immunoglobulin biological products in Nanjing from 2016 to 2018. Methods:Statistics and analysis were carried out on the varieties, sales amount, composition ratio, medication frequency(DDDs) and daily drug cost(DDC) of albumin and immunoglobulin biological products from 37 hospitals in Nanjing from 2016 to 2018. Results:The total amount of use of albumin and immunoglobulin biological products had increased year by year, with an average annual growth rate of 19.54%. The three-year sales of human biological albumin, intravenous immunoglobulin and rabies immunoglobulin were ranked in the top three, and the proportion was more than 90%. The three-year DDDs of human serum albumin, intravenous immunoglobulin and hepatitis B human immunoglobulin were ranked in the top three. Conclusion:The albumin and immunoglobulin biological products in Nanjing are widely used in clinical application, and the usage and use amount are increasing rapidly.
作者
计成
李杰
Ji Cheng;Li Jie(Department of Pharmacy,The Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing 210008,China;Department of Pharmacy,Zhangjiagang Hospital Affiliated to Nanjing University of TCM)
出处
《药物流行病学杂志》
CAS
2020年第7期484-487,共4页
Chinese Journal of Pharmacoepidemiology
基金
南京大学医院管理研究所管理项目课题(编号:NDYG2019006)。
